AS
ASND
Methodology breakdown computing — it will appear here on its own.
Ascendis Pharma A/S - ADR (ASND) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for ASND — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 57.20 | NEUTRAL |
| Stochastic %K (14) | 71.79 | NEUTRAL |
| CCI (20) | 72.00 | NEUTRAL |
| Williams %R (14) | -28.21 | NEUTRAL |
| MACD (12,26,9) | 0.71 | BUY |
| ROC (10) | 6.31 | BUY |
| Momentum (10) | 15.72 | BUY |
| EMA (10) | 262.84 | BUY |
| SMA (10) | 263.74 | BUY |
| EMA (20) | 259.74 | BUY |
| SMA (20) | 257.72 | BUY |
| EMA (30) | 257.76 | BUY |
| SMA (30) | 254.92 | BUY |
| EMA (50) | 254.55 | BUY |
| SMA (50) | 257.53 | BUY |
| EMA (100) | 247.30 | BUY |
| SMA (100) | 245.36 | BUY |
| EMA (200) | 234.81 | BUY |
| SMA (200) | 233.53 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Ascendis Pharma A/S - ADR
Healthcare · Biotechnology
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-08-31
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
Weak — low conviction, small size or skip
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 62 |
| ⏰ 4H | BEARISH | 36 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.